Apoptosis

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

Retrieved on: 
Monday, April 8, 2024
Amylyx Pharmaceuticals, Patient, Defendant, Apoptosis, ALS, Pharmaceutical industry

LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Monday, April 8, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
MDM2, Apoptosis, ASH, Drug discovery, PD, Patient, Tumor microenvironment, Cancer, Doctor of Philosophy, TPD, Proteomics, AACR, Society, Therapy, Drug development, Downregulation and upregulation, VHL, STAT3, Pharmaceutical industry

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company’s unique target selection strategy and strong preclinical to clinical translation observed across the Company’s first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.

Key Points: 
  • For these reasons, STAT3 degraders may provide a solution to the development of targeted and selective drugs to address multiple STAT3 dependent pathologies.
  • Additionally, this unique mechanism of action led to induction of proinflammatory anti-tumorigenic transcriptional signatures in the tumor microenvironment.
  • This has resulted in robust antitumor activity in patients, as reported in the Company’s latest clinical update at the American Society of Hematology (ASH) Annual Meeting in December 2023.
  • The Company expects to complete both studies and share additional clinical data to inform the programs’ next development steps in 2024 at upcoming medical meetings.

AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Sunday, April 7, 2024
Apoptosis, ALS, Patient, AMX0035, Amyotrophy, Complaint, Court, Food, Person, Pharmaceutical industry

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AMLX .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AMLX .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit – AMLX

Retrieved on: 
Thursday, April 4, 2024
Apoptosis, ALS, Telephone, Patient, LLP, CLASS, NEXT, COST, Court, Cryptocurrency

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.
  • Follow the link below to get more information and be contacted by a member of our team:
    AMLX investors may also contact Joseph E. Levi, Esq.
  • If you suffered a loss in Amylyx during the relevant time frame, you have until April 9, 2024 to request that the Court appoint you as lead plaintiff.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.

Investors who lost money on Amylyx Pharmaceuticals, Inc. (AMLX) should contact The Gross Law Firm about pending Class Action - AMLX

Retrieved on: 
Wednesday, April 3, 2024
NEXT, Amylyx Pharmaceuticals, Patient, Apoptosis, Fraud, ALS, Security (finance)

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).
  • Shareholders who purchased shares of AMLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024

Retrieved on: 
Wednesday, April 3, 2024
Apollon, Apoptosis, Tumor microenvironment, Cancer, Abstract, AACR, Therapy, Escape Room, Pharmaceutical industry

MARTINSRIED, Germany and MUNICH, Germany, April 03, 2024 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs, today announces that it will present new data on its lead I/O drug candidates OMX-0407 and IOMX-0675, plus its proprietary iOTarg™ screening platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place from April 5-10, 2024, in San Diego, California.

Key Points: 
  • "We are excited to share updates on our two lead I/O programs targeting a broad range of solid tumor indications and our high-throughput target screening platform – iOTarg.
  • Through tyrosine kinase signaling, OMX-0407 interferes with cell cycle regulation and cancer cell proliferation.
  • Complementary to this direct mode of action, OMX-0407 also potentiates tumor cell apoptosis in response to death receptor ligands including tumor necrosis factor through salt inducible kinase signaling.
  • With this dual mode of action, OMX-0407 has shown striking single-agent efficacy in multiple pre-clinical tumor models.

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

Retrieved on: 
Monday, April 1, 2024
Patient, Defendant, Apoptosis, ALS, Pharmaceutical industry

LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc.

Retrieved on: 
Monday, April 1, 2024
Apoptosis, ALS, District court, Patient, AMX0035, News, Prescription, Complaint, Action Replay, Amylyx Pharmaceuticals, Food, Court, Advertising, Pharmaceutical industry

If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.

Key Points: 
  • If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Sunday, March 31, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.